Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia

Bibliography

• National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia-Version 4.2013. Available from: http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
   Google Scholar
• Sawiers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-72
   PubMed Web of Science ®Google Scholar
• Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007;26(1):11-20
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature 1985;315(6022):758-61
   PubMed Web of Science ®Google Scholar
• Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah N, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. N Engl J Med 2006;354:2531-41
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah N, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
   PubMed Web of Science ®Google Scholar
• Available from: http://ec.europa.eu/health/documents/community-register/index_en.htm
   Google Scholar
• Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22(4):337-58
   PubMed Web of Science ®Google Scholar
• Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008;49(1):19-26
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole- 5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63(2):375-81
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Ye F, Wang YD, et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001;44:3965-77
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-22
   PubMed Web of Science ®Google Scholar
• Boschelli DH, Boschelli F, Wu B, et al. SKI-606 and beyond. Hematol Rep 2005;1:28-31
   Google Scholar
• Mancini M, Brusa G, Zuffa E, et al. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606. Leuk Res 2007;31(7):979-87
   PubMed Web of Science ®Google Scholar
• Abbas R, Hug BA, Leister C, et al. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011;51(12):1721-7
   PubMed Web of Science ®Google Scholar
• Abbas R, Chalon S, Leister C, et al. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol 2013;71(1):123-32
   PubMed Web of Science ®Google Scholar
• Abbas R, Hug BA, Leister C, et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012;69(1):221-7
   PubMed Web of Science ®Google Scholar
• Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469-71
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-76
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Brümmendorf TH, Kim WH, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Haematologica In press
   Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2014;119(15):3403-12
   Web of Science ®Google Scholar
• Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012;87(11):E125-8
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic–phase chronic myeloid leukemia, Results from the BELA trail. J Clin Oncol 2012;30(28):3486-92
   PubMed Web of Science ®Google Scholar
• An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. ASH 2010. Available from: https://ash.confex.com/ash/2010/webprogram/Paper31733.html
   Google Scholar
• Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012;3898-905
   PubMedGoogle Scholar
• Gambacorti-Passerini C, Piazza R. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in “long-term” safety and efficacy. Am J Hematol 2011;86(7):531-2
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200 [abstract]. J Clin Oncol 2010;28:abstract 6509
   Web of Science ®Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23(3):477-85
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Kim DK, et al. Safety and efficacy of bosutinib in Philadelphia chromosome–positive advanced leukemia following imatinib and other tyrosine kinase inhibitors. Leukemia; 2014
   Google Scholar
• Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908-14
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103(7):553-61
   PubMedGoogle Scholar
• Konig H, Holyoake TL, Bhatia R, et al. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008;111(4):2329-38
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-17
   PubMed Web of Science ®Google Scholar